The authors present an interesting study suggesting that human platelets prepared in blood transfusion services could become a useful source for a novel lyophilized therapeutic agent capable of increasing thrombus formation in vivo. Besides the promising outcomes of their in vitro and in vivo model investigations, the authors correctly discuss the need for phase I safety studies before a large clinical trial can be performed in the setting of acutely bleeding medical or surgical patients.

– Paolo Rebulla